Patent Law Weblog
recent posts
- Hikma v. Amarin at the Supreme Court: The Parties’ Opening Briefs – Part II
- Retired Judges File Amicus Brief in Support of Judge Newman
- Hikma v. Amarin at the Supreme Court: The Parties’ Opening Briefs
- Teva Pharmaceuticals International v. Eli Lilly & Co. (Fed. Cir. 2026)
- USPTO Extends Artificial Intelligence Search Automated Pilot Program (ASAP!)
about
Month: March 2013
-
March 10-13, 2013 – Genes & Diagnostics: A Myriad of Issues in Biotech IP (Cold Spring Harbor Laboratory) – Cold Spring Harbor Laboratory March 13, 2013 – First to File: Final Rules and Guidance — Navigating Significant Changes to Derivation Practice, What Constitutes Prior Art and More (Strafford) – 1:00 – 2:30 pm (EDT) March…
-
The Biotechnology Industry Organization (BIO) will be holding its annual BIO International Convention on April 22-25, 2013 in Chicago, IL. Founded in 1993, BIO is a nonprofit association seeking supportive biotechnology policies on behalf of more than 1,100 biotechnology companies, academic institutions, state biotechnology centers, and related organizations across the United States and in more…
-
American Conference Institute (ACI) will be holding its next Paragraph IV Disputes conference on May 7-8, 2013 in New York, NY. The conference will allow attendees to: • Assess how new PTO proceedings will influence the course of Hatch-Waxman litigation;• Understand how new 271(e)(1) controversies under Claussen and Momenta will affect ANDA filings;• Decipher the…
-
McDonnell Boehnen Hulbert & Berghoff LLP will be offering a live webinar entitled "Optimizing the Discovery Process: Home and Abroad" on April 16, 2013 from 10:00 am to 11:15 am (CT). MBHB attorneys Richard Carden and Kurt Rohde will address recent issues in discovery and how both in-house and outside counsel may optimize the discovery…
-
By Donald Zuhn — In a 2-1 decision issued earlier today, the Federal Circuit affirmed a determination by the Board of Patent Appeals and Interferences upholding the rejection of the claims of U.S. Application No. 10/650,509 for obviousness-type double patenting over U.S. Patent No. 7,601,685. The '509 application, which is assigned to the California Institute…
-
By Donald Zuhn — Last April, Abbott Laboratories filed a Citizen Petition with the U.S. Food and Drug Administration, asking the agency to refrain from accepting biosimilar applications under the Biologics Price Competition and Innovation Act (BPCIA) that cite reference products (biologics) for which a biologics license application (BLA) was submitted to the FDA prior…
-
On 26 February 2013, the UK government announced a proposed change to the Patents Act to exempt clinical and field trials, as well as "health technology assessments," e.g., tests to obtain data to support assessment by the National Institute for Health and Clinical Excellence (NICE), for any new drugs from any claim of patent infringement.…
-
In January, the Mexican Senate published a Bill adding article 23 bis to the Industrial Property Law (IP Law). This Bill intends to establish a "special" life term for patents claiming a substance or a mix of substances regulated by article 221, sections I to III of the Health Law; that is: drugs, active ingredients…
-
By Charlotte Teall — Background Rule 140 EPC does not explicitly relate to the correction of patents, but to the correction of EPO decisions. However, until now, the European Patent Office (EPO) has allowed patentees to correct the text of a Patent after grant using Rule 140 EPC. Recent decision (G1/10) The Enlarged Board of…
-
By Donald Zuhn — Last month, companion bills were introduced in the House and Senate that would require Federal agencies to develop public access policies relating to research conducted by employees of the agency or using funds administered by the agency. The Fair Access to Science and Technology Research Act of 2013 ("FASTR") was introduced…
Patent Docs 